RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Diluted EPS

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndDiluted EPS (USD)YoY (%)
Dec 31, 2024-2.1-114.97%
Dec 31, 202313.9+8.35%
Dec 31, 202212.8+42.29%
Dec 31, 20219-12.44%
Dec 31, 202010.3+128.16%
Dec 31, 20194.5-44.25%
Dec 31, 20188.1+677.88%
Dec 31, 20171-326.09%
Dec 31, 2016-0.5-80.09%
Dec 31, 2015-2.3-26.43%
Dec 31, 2014-3.1+58.59%
Dec 31, 2013-2+296.00%
Dec 31, 2012-0.5-457.14%
Dec 31, 20110.1-103.71%
Dec 31, 2010-3.8

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)